The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Transfer of Certolizumab in Breast Milk Not a Concern

Transfer of Certolizumab in Breast Milk Not a Concern

November 22, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study.

You Might Also Like
  • Certolizumab Pegol Usage Compatible with Breastfeeding
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
  • Certolizumab Combo Helps Curb RA Damage

“These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina, and colleagues write in an abstract presented Nov. 14 at the American College of Rheumatology annual meeting in Washington, D.C.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding,” they point out.

Until now, there were “limited and non-validated” data on the potential transfer of anti-TNF agents into breast milk, they note.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The CRADLE study—short for Concentration of Cimzia in Mature Breast Milk of Lactating Mothers—was a prospective, postmarketing safety and pharmacokinetic study designed to evaluate concentrations of the drug in breast milk, and to estimate average daily infant dose of maternal certolizumab.

CRADLE involved 17 lactating mothers receiving certolizumab for an approved indication.

Using a highly sensitive assay, certolizumab was undetectable in 56% of milk samples collected at various time points, the researchers report.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

When detectable, concentrations of the drug were less than three times the lower limit of quantification (less than 1% of expected plasma concentration of a therapeutic dose), “indicating no to minimal transfer” of certolizumab from plasma to breast milk, the researchers say.

The relative infant dose—the daily amount of the drug ingested by infants—was below 0.5% of maternal dose, and less than 10% is considered unlikely to be of clinical concern, they note.

In addition, they say certolizumab absorption by infants through breast milk is “unlikely due to its Fc-free molecular structure and the low bioavailability of biologics after oral administration.”

The study was funded by UCB Pharma. Four authors are employees of the company.

Dr. Clowse did not respond to a request for comment by press time.


Reference

  1. Clowse MEB, Förger F, Hwang C, et al. Evaluating transfer of certolizumab pegol into breast milk: Results from a prospective, post-marketing, multi-center pharmacokinetic study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: breast milk, Certolizumab Pegol, TNF, TNF inhibitor

You Might Also Like:
  • Certolizumab Pegol Usage Compatible with Breastfeeding
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
  • Certolizumab Combo Helps Curb RA Damage
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)